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Abstract
Malaria transmission blocking vaccines (TBVs) are considered an effective means to control and eventually eliminate malaria.
The Pfs25 protein, expressed predominantly on the surface of the sexual and sporogonic stages of Plasmodium falciparum
including gametes, zygotes and ookinetes, is one of the primary targets for TBV. It has been demonstrated that plants are an
effective, highly scalable system for the production of recombinant proteins, including virus-like particles (VLPs). We
engineered VLPs (Pfs25-CP VLP) comprising Pfs25 fused to the Alfalfa mosaic virus coat protein (CP) and produced these
non-enveloped hybrid VLPs in Nicotiana benthamiana plants using a Tobacco mosaic virus-based ‘launch’ vector. Purified
Pfs25-CP VLPs were highly consistent in size (19.362.4 nm in diameter) with an estimated 20–30% incorporation of Pfs25
onto the VLP surface. Immunization of mice with one or two doses of Pfs25-CP VLPs plus AlhydrogelH induced serum
antibodies with complete transmission blocking activity through the 6 month study period. These results support the
evaluation of Pfs25-CP VLP as a potential TBV candidate and the feasibility of the ‘launch’ vector technology for the
production of VLP-based recombinant vaccines against infectious diseases.
Citation: Jones RM, Chichester JA, Mett V, Jaje J, Tottey S, et al. (2013) A Plant-Produced Pfs25 VLP Malaria Vaccine Candidate Induces Persistent Transmission
Blocking Antibodies against Plasmodium falciparum in Immunized Mice. PLoS ONE 8(11): e79538. doi:10.1371/journal.pone.0079538
Editor: Luzia Helena Carvalho, Centro de Pesquisa Rene Rachou/Fundac¸a˜o Oswaldo Cruz (Fiocruz-Minas), Brazil
Received June 20, 2013; Accepted September 20, 2013; Published November 18, 2013
Copyright:  2013 Jones et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by the Bill & Melinda Gates Foundation (grant number OPPGH5201; http://www.gatesfoundation.org). The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: vyusibov@fraunhofer-cmb.org
Introduction
Malaria is a mosquito-borne, life-threatening, infectious disease
caused by Plasmodium parasites. According to the World Malaria
Report 2012, about 219 million clinical cases of malaria were
reported worldwide in 2010, predominantly in developing
countries in sub-Saharan Africa and South-East Asia, causing
approximately 660 000 deaths, mostly among African children
under the age of 5 years. Of the four species of malaria parasites
that infect humans, Plasmodium falciparum is responsible for the
majority of deaths (http://www.who.int/mediacentre/factsheets/
fs094/en/index.html; http://www.rollbackmalaria.org/keyfacts.
html).
The spread of the disease in endemic regions is controlled by the
use of insecticide-treated bed nets and indoor residual spraying.
Chemotherapy is available for curative treatment but recurring
drug resistance compromises the efficiency of both old and new
antimalarial medicines (http://whqlibdoc.who.int/publications/
2010/9789241547925_eng.pdf). Thus, effective vaccines for the
control and prevention of malaria are urgently needed, as
vaccination remains one of the most efficient and cost-effective
methods for controlling infectious diseases. Current malaria
vaccine candidates have so far not shown satisfactory levels of
protection [1,2,3,4,5,6]. Most research activities have been focused
on pre-erythrocytic and asexual stages of the parasite life cycle,
preventing the occurrence or multiplication of pathogenic asexual
parasite forms [7]. Recently, the Malaria Eradication Research
Agenda Consultative Group on Vaccines has set as a core goal
that any malaria vaccine program needs to reduce transmission as
well as morbidity [8]. These initiatives to eliminate/eradicate
malaria have intensified the interest to develop transmission
blocking (TB) vaccines (TBVs). TBVs aim to prevent sexual stage
parasites ingested by female Anopheles mosquitoes from undergoing
successful sporogonic development, thus preventing transmission
from human to mosquito and subsequent spread of parasites in
endemic populations. Identified targets of effective TB immunity
are proteins expressed on the surface of gametocytes/gametes,
zygotes and ookinetes. More specifically, Pfs25, Pfs28, Pfs48/45,
and Pfs230 have been shown to induce antibodies with significant
TB activity when ingested by the mosquito vector along with P.
falciparum gametes during a blood meal [9,10]. Inhibition of oocyst
formation prevents generation of infective sporozoites in the
salivary glands of the mosquito and subsequent transmission of the
parasite to the next human host during the mosquito’s blood meals
[11].
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Pfs25, one of the primary targets for TBV development, is a
member of a protein family characterized by the presence of
epidermal growth factor (EGF)-like repeat motifs, numerous
cysteine residues and a complex tertiary structure [12]. Therefore,
it has been difficult to produce Pfs25 with accurate conformation
in heterologous systems. Additionally, Plasmodium parasites lack the
N-linked glycosylation machinery, and many Plasmodium proteins
contain multiple potential glycosylation sites that are aberrantly
glycosylated when expressed in any of the available eukaryotic
hosts [13]. Despite these challenges, recent success has been
achieved with recombinant versions of Pfs25 proteins produced in
yeast that are emerging as prominent TBV candidates
[14,15,16,17,18,19,20,21,22], the leading candidate being a Pichia
pastoris produced Pfs25 (PpPfs25H-A) chemically conjugated to the
mutant, non-toxic ExoProtein A (EPA) of Pseudomonas aeruginosa
[23] (http://www.clinicaltrials.gov/ct2/show/NCT01434381).
During the last two decades, several groups have demonstrated
the potential of plants as a safe, cost-effective and highly scalable
platform for production of recombinant vaccine antigens and
therapeutic proteins (for reviews see refs. [24,25]). We have
developed a plant virus vector (‘launch’ vector)-based transient
expression system [26] that has been successfully used to produce
efficacious subunit vaccine candidates against anthrax, plague and
influenza in Nicotiana benthamiana plants [27,28,29,30,31,32]. In a
recent study, this system has also been utilized to produce variants
of the soluble, full-length Pfs25 antigen that varied in immuno-
genicity and TB activity [33].
Virus-like particles (VLPs) are a class of subunit vaccines with
virus-like morphology which do not contain infectious genetic
material. This morphology is believed to be associated with strong
protective immunity [34]. All four recombinant licensed vaccines,
hepatitis B virus (EngerixH and Recombivax HBH) and human
papillomavirus (CervarixH GardasilH), are based on highly purified
VLPs. A wide variety of VLP-based vaccine candidates against
target pathogens have been produced in different expression
systems, including mammalian, plant, insect, yeast and bacterial
cells, as well as cell-free platforms (for a review see ref. [35]). In
addition to VLPs assembled from target pathogen components,
chimeric VLPs have also been produced with target antigens
genetically fused or chemically conjugated to viral structural
proteins with self-assembly capability, such as the malaria vaccine
candidate RTS,S [6,36].
Plant viral coat proteins (CPs) have also been used to display
immunogenic target antigens on the surface of self-assembling
VLPs. For example, HIV-1 gp41 epitope fused to either S protein
of Cowpea mosaic virus (CPMV) or CP of Potato virus X (PVX)
yields chimeric VLPs [37,38,39]. Similarly, malaria merozoite
peptide P109 fused to CP of CPMV yielded chimeric VLPs that
elicited P. falciparum-specific serum antibodies in rabbits [40].
Alfalfa mosaic virus (AlMV) has also been used extensively to
engineer chimeric VLP vaccines. For example, peptides from
HIV-1 gp120 and rabies virus G protein fused to AlMV CP and
expressed in N. benthamiana elicited strong immune responses in
mice and non-human primates, respectively [41,42]. Also, AlMV
CP-based chimeric VLPs presenting B and T cell epitopes from
GP and NP of rabies virus transiently produced in spinach and
tested as a booster vaccine in a Phase 1 clinical trial enhanced
rabies virus neutralizing antibody titers in human volunteers
previously immunized with a commercial rabies vaccine [43].
Here, we describe the engineering of VLPs comprising Pfs25
fused to AlMV CP (Pfs25-CP VLP), production of these VLPs in
N. benthamiana using the ‘launch’ vector-based transient expression
technology, establishment of purification processes, and evaluation
of the purified VLPs in mice for TB activity.
Materials and Methods
Ethics Statement
All animal studies reported here were conducted in compliance
with the Animal Welfare Act regulations in the Guide for Care and
Use of Laboratory Animals. All procedures were approved by the
Institutional Animal Care and Use Committee at the University of
Delaware (Newark, DE) under Animal Use Protocol Number
1171.
Cloning and Expression
The gene sequence encompassing amino acids 23–193 of Pfs25
of P. falciparum (NCBI accession number AAF63684) was
engineered as an N-terminal fusion to AlMV CP (accession
number NP_041195) to form a fusion protein, Pfs25-CP. To
eliminate potential N-linked glycosylation sites in the Pfs25
protein, two point mutations were introduced at positions 112
and 187 to replace asparagine with glutamine (N112Q and
N187Q). The native Pfs25 signal peptide was replaced at the N-
terminus with the signal peptide of tobacco pathogenesis-related
1a protein precursor of Nicotiana tabacum (BAA14220), which is
predicted to be subsequently removed during protein expression
and secretion into the endoplasmic reticulum. The construct
containing the Pfs25-CP sequence was optimized for plant
expression by GeneArt (Regensburg, Germany) and cloned into
the Tobacco mosaic virus (TMV)-based ‘launch’ expression vector
pGR-D4 [26,31]. The resulting vector was introduced into
Agrobacterium tumefaciens strain GV3101 by electroporation, the
culture was grown overnight in minimal media, and transformed
bacteria were vacuum infiltrated into leaves of 6-week-old
hydroponically grown N. benthamiana as described previously
[31,44].
Purification
Seven days post-infiltration, plant biomass was harvested,
homogenized and clarified by continuous flow centrifugation
and filtration through a 2.5 mm pre-filter followed by a 0.8/
0.2 mm dead-end filter. Recombinant particles were precipitated
using polyethylene glycol and re-suspended in Na-Phosphate
buffer (95 mM Na-Phosphate, 5% Na-Pyrophosphate, pH 7.4).
The re-suspended Pfs25-CP VLP preparation was further purified
using hydrophobic interaction chromatography (HIC) and ceram-
ic hydroxyapatite (CHT) type II chromatography. Target particles
bound to the CHT resin were eluted with 150 mM Na-Phosphate
buffer (150 mM Na-Phosphate, 1.5 mM Na-Pyrophosphate,
pH 7.4). The CHT elution was subsequently concentrated by
ultrafiltration in a cassette-style ultrafiltration/diafiltration system
with a 100 kDa MWCO membrane. The sample was concentrat-
ed at least 30-fold, filtered through a 0.2 mm filter and held
overnight at 4uC. The concentrated CHT elution was passed over
a size-exclusion chromatography (SEC) column. SEC was
performed in phosphate-buffered saline (PBS –137 mM NaCl,
2 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4). The eluted
target peak was concentrated and exchanged into the final bulk
storage buffer (50 mM Na-Phosphate, pH 7.4).
Characterization
Proteins were separated using 10% acrylamide in sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and stained with Coomassie (Gel Code Blue, Pierce, Rockford,
IL). The concentration of Pfs25-CP VLP was estimated relative to
bovine serum albumin (BSA) from in-gel densitometry measure-
ments analyzed with the GeneTools analysis software (Syngene
USA, Frederick, MD). Replicate measurements of a single batch
A Plant-Produced Pfs25 VLP Malaria TBV Candidate
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using this method indicate a percent coefficient of variation of 7%
(seven independent measurements over 12 months). This concen-
tration of Pfs25 was used to prepare vaccines for immunization.
Immunoblotting was performed by wet transfer of sample to a
PVDF membrane, subsequently blocked with I-Block (Applied
Biosystems, Carlsbad, CA). Target bands were detected using a
Pfs25-specific monoclonal antibody (mAb), 4B7, or an anti-AlMV
CP polyclonal serum (Agdia, Inc, Elkhart, IN), followed by a
species-specific horseradish peroxidase-conjugated secondary an-
tibody (Jackson ImmunoResearch, West Grove, PA). Analytical
SEC was performed by passage over a SRT-1000 4.66300 mm
column (Sepax, Newark, DE) in 50 mM phosphate buffer. The
exclusion limit for this column per the manufacturer is 7.5 MDa
with a lower resolution limit of 50 kDa. The void volume was
empirically determined to be at 5 mL and thyroglobulin
(670 kDa), BSA (66 kDa), and uracil (120 Da) were used as
column elution standards.
Dynamic light scattering (DLS) was performed on a DyanPro
Plate Reader instrument (Wyatt technologies, Santa Barbara, CA).
All measurements were performed at 25uC with temperature
controlled by the instrument. Before the measurements, all
samples were centrifuged at 10,000 rpm for 5 minutes. Presented
hydrodynamic radius (Rh) is an average value of 10 measurements.
The Dynamics 7.1.7 software at optimized resolution was used for
the analysis of the collected data. The mean Rh and percent
polydispersity (%Pd) were estimated on the basis of an autocor-
relation analysis of scattered light intensity based on the
translational diffusion coefficient, by Stokes–Einstein equation:
Rh~
kT
6pgD25
0C
W
where k is the Boltzmann’s constant, T is the absolute
temperature, g is the viscosity of water and D25
0C
W is the
translational diffusion coefficient.
N-terminal sequencing was performed by Proteos, Inc.
(Kalamazoo, MI). Electron microscopy (EM), both negative
staining and immunogold labeling, were performed at the Bio-
Imaging Center at Delaware Biotechnology Institute (University of
Delaware, Newark, DE). The particle size was measured from the
negative stained Pfs25-CP VLP images using the semiautomatic
ImageJ analysis software (Version 1.47; Rasband WS, ImageJ, U.
S. National Institutes of Health, Bethesda, Maryland, USA,
http://imagej.nih.gov/ij/, 1997–2012). The average diameter is
reported with the standard deviation. The anti-Pfs25 mAb, 4B7,
was used as the primary antibody for the immunogold staining,
followed by a gold-labeled species-specific secondary antibody
(Aurion, The Netherlands).
Assessment of Pfs25-CP VLP Immunogenicity and TB
Activity
Pfs25-CP VLPs were evaluated for immunogenicity and TB
activity in mice. In the first two studies, groups of 6–8-week-old
BALB/c mice (Harlan Laboratories Inc, Indianapolis, IN), 5–6
animals per group, were immunized intramuscularly with an
amount of Pfs25-CP VLP equivalent to 1.0, 0.1 or 0.01 mg of
Pfs25 with or without 0.3% AlhydrogelH (Brenntag-Biosector,
Denmark) on study days 0 and 21. The binding of Pfs25-CP VLP
to AlhydrogelH was confirmed by examination of post-incubation
supernatants after the solids had been pelleted by centrifugation.
No Pfs25-CP was detectable in solution by UV-Visible spectros-
copy at the time of immunization. Control animals received 5.0 mg
of native CP VLPs plus AlhydrogelH. In a third study, the
immunogenicity of Pfs25-CP VLPs was evaluated after a single
dose. Groups of 6 BALB/c mice were immunized intramuscularly
with an amount of Pfs25-CP VLP equivalent to 0.2, 1.0, 5.0 or
25 mg of Pfs25 with 0.3% AlhydrogelH. Control animals received
25 mg of CP VLPs plus AlhydrogelH. Serum samples from the
immunized mice were collected on study days 0, 21, 42, 70, 112
and 168 for the first and third studies and on study days 0, 21, 42,
84, 112 and 140 for the second study. All samples were assessed for
Pfs25-specific IgG titers by enzyme-linked immunosorbent assay
(ELISA) as well as for TB activity by standard membrane feeding
assay (SMFA) post boost and at study termination.
ELISA
Pfs25-specific IgG titers were measured by ELISA using 96-well
MaxiSorp plates (Nunc, Rochester, NY) coated with 1 mg/mL of
plant-produced Pfs25 (non-CP fusion) in PBS and incubated
overnight at 4uC. After blocking with 0.5% I-Block (Life
Technologies, Grand Island, NY) in PBS with 0.1% Tween 20,
serum samples were plated at a starting dilution of 1:100 and
titrated in 5-fold dilutions. Target-specific IgG was detected using
a goat anti-mouse IgG horseradish peroxidase-conjugated anti-
body (Jackson ImmunoResearch, West Grove, PA). All plates were
visualized using SigmaFastTM o-phenylenediamine dihydrochlo-
ride (OPD) (Sigma-Aldrich, St. Louis, MO) as a substrate with an
acid stop. Reciprocal serum dilutions that gave a mean absorbance
value (OD490) 4 times greater than background (pre-immune
serum) were determined as end point titers.
SMFA
SMFA was performed to evaluate TB activity as previously
described [45,46]. Briefly, 30 mL of mouse sera (pooled per group)
was mixed with 90 mL of naı¨ve human serum and 150 mL of
in vitro matured gametocyte culture of P. falciparum (NF54 line).
This mixture was fed to Anopheles stephensi mosquitoes (Nijmegen
strain) through a membrane-feeding device in the presence of test
or control sera. Fully engorged mosquitoes were separated and
held at 26uC. Seven days later, midguts of 20 mosquitoes were
examined for oocysts. Prevalence and intensity of oocysts were
determined and TB activity was expressed as percentage reduction
in the arithmetic mean oocyst number in test versus controls. A
SMFA was considered successful when at least 85% of the
mosquitoes dissected in the control groups carried oocysts. For
comparison of groups and statistical analysis, a non-parametric test
(not normally distributed) was applied by comparing the medians
of two groups using the Mann-Whitney test or by comparing three
or more groups using the Kruskal-Wallis test. If significance was
indicated, Dunn’s analysis was used for comparison with the
control group.
Results
Pfs25-CP VLP Engineering, Expression in N. benthamiana,
Purification and Characterization
Pfs25 was engineered as an in-frame fusion to the N-terminus of
AlMV CP, cloned into the ‘launch’ vector pGR-D4, transformed
into A. tumefaciens and introduced into N. benthamiana by agroinfil-
tration (Fig. 1). The two putative N-linked glycosylation sites in
Pfs25 (N112Q and N187Q) were mutated to eliminate potential
N-glycosylation, to mimic the non-glycosylated state of the protein
in P. falciparum and to reduce heterogeneity of the resulting Pfs25-
CP VLPs. A third potential N-linked glycosylation site at N143 is
predicted to have lower potential for glycosylation than the two
mutated sites, and was therefore not changed. In addition, based
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on the sequence of AlMV CP (Fig. 2A), CP is not predicted to
contain any N-linked glycosylation consensus sites (NxT/S).
Infiltrated plants accumulated recombinant protein with peak
levels of approximately 50 mg/kg at 7 days post-infiltration (dpi).
For VLP production, aerial biomass was harvested at 7 dpi.
Target VLPs were purified using polyethylene glycol precipitation
followed by a three-column chromatography process. This
approach yielded target of .85% purity comprising three main
polypeptide chains (Fig. 2A). One chain, accounting for 20–30%
of the product, corresponds in size to Pfs25-CP fusion (band
marked by arrowhead ‘a’ in Fig. 2A) and the other two chains
correspond approximately in size to truncated CP (bands marked
by arrowheads ‘b’ & ‘c’ in Fig. 2A). Western blot analysis using an
anti-Pfs25 mAb and anti-AlMV CP polyclonal serum confirmed
that the band at 50 kDa includes Pfs25 and CP and the two bands
at ,25 kDa include CP but not Pfs25 (Fig. 2B). N-terminal
sequencing confirmed that while the 50 kDa polypeptide chain
starts with the Pfs25 sequence, the ,25 kDa polypeptide chains
start with the truncated CP sequence. Thus, the ,25 kDa bands
appear to result from in planta cleavage of the Pfs25-CP fusion
polypeptide.
Transmission EM analysis of Pfs25-CP revealed VLPs of
consistent size of 19.362.4 nm in diameter based on 250 manual
measurements of individual particles (Fig. 3A). The presence of the
Pfs25 antigen was confirmed by immunogold labeling (Fig. 3B).
Furthermore, DLS analysis demonstrated that the particle
population has a Rh of 14.161.1 nm with low polydispersity
(,15%) (Fig. 3C). This low size range distribution was confirmed
by analytical SEC that showed a single main peak eluting at
9.5 mL (Fig. 3D). Taken together, these data indicate that Pfs25-
CP VLPs represent a homogenous particle species, and that the
Pfs25-CP fusion and truncated CPs co-assemble in planta to form
VLPs.
Immunogenicity of Pfs25-CP VLPs and Induction of TB
Activity
Mice were immunized with an amount of Pfs25-CP VLP
equivalent to 1.0 or 0.1 mg of Pfs25 with and without AlhydrogelH
on study days 0 and 21. The kinetics of the Pfs25-specific IgG
response showed a similar pattern for both doses of Pfs25-CP
VLPs with a 2-log enhancement in IgG titer with the addition of
AlhydrogelH (Fig. 4A). Antibody responses for both doses peaked
following the booster dose on study day 42 with levels of Pfs25-
specific IgG remaining constant through the end of the study, day
168 (6 months). The dominant IgG subclass throughout the
antibody kinetics was IgG1 (data not shown), likely attributed to
the use of AlhydrogelH adjuvant, which has been shown to initiate
strong Th2 type responses in mice [20,47]. As expected, no Pfs25-
specific IgG was detected in the serum of animals immunized with
CP VLPs only.
Serum samples collected on study days 70 and 168 (6 months)
showed that both 1.0 and 0.1 mg adjuvanted dose groups had
100% TB activity 7 weeks after the booster dose and maintained
that high level of TB activity through day 168 (Table 1). In the
control and non-adjuvanted dose groups, the infection intensity
(median number of oocyst per mosquito) ranged from 9–13 on
study day 70 and from 1–3 at 6 months (Table 1). In addition,
oocyst prevalence (% infected mosquitos per feeder) in these
groups was above 90% on study day 70 and from 65–95% at 6
months. Therefore, a second experiment was conducted to
reproduce the results from the first study and further reduce the
dose of Pfs25-CP VLPs tested.
In this second study, mice were immunized with an amount of
Pfs25-CP VLP equivalent to 1.0, 0.1 or 0.01 mg of the Pfs25 plus
AlhydrogelH on study days 0 and 21. The kinetics of the Pfs25-
specific IgG response showed a similar pattern to the previous
study, with the 1.0 and 0.1 mg doses inducing similar levels of IgG
that peaked post boost on study day 42 and were maintained
through study day 140 (5 months), the longest time tested in this
study (Fig. 4B). In contrast, the 0.01 mg dose showed a similar
pattern of IgG production, but the magnitude of the response was
greatly reduced (Fig. 4B).
Serum samples collected on study days 42 and 140 showed that
1.0 and 0.1 mg doses with AlhydrogelH elicited 100% TB activity
following the booster dose and maintained a high level of TB
activity, 98–99%, through day 168 (Table 2). In contrast, the
0.01 mg dose showed a low level of TB activity on both days 42
and 140, indicating that the cut-off value for an effective Pfs25
dose that induces high TB activity in mice is between 0.1 and
0.01 mg. The oocyte prevalence in the 1.0 and 0.1 mg dose groups
was 0% on study day 42 and 10% on study day 140 compared to
values of greater than or equal to 90% for the 0.01 mg dose and
control groups. The infection intensity remained at 0 in the 1.0
and 0.1 mg dose groups, while the 0.01 mg and control groups
ranged from 4–14. The combined data show induction of
reproducible immune responses with very high levels of TB
activity after two doses of Pfs25-CP VLP.
Figure 1. Schematic diagram of the ‘launch’ vector. Following agroinfiltration of plants, the sequence between the left border (LB) and the
right border (RB) of the plasmid vector is transferred from Agrobacteria into plant cells where expression of the engineered TMV genome is driven by
the Cauliflower mosaic virus (CaMV) 35S promoter. TMV replicase then drives amplification of primary transcript, and Pfs25-CP accumulation is then
driven by the TMV CP subgenomic promoter (light blue box). Movement protein (MP) facilitates cell-to-cell transfer of viral sequences and is driven by
the MP subgenomic promoter (dark blue box).
doi:10.1371/journal.pone.0079538.g001
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The TB activity of Pfs25-CP VLPs in mice was next evaluated
following a single administration. In this study, mice were
immunized with a dose escalation of the Pfs25 equivalent ranging
from 0.2 to 25 mg with AlhydrogelH, and Pfs25-specific antibody
responses were monitored over time. For all but the lowest dose
group (0.2 mg of Pfs25), the anti-Pfs25 IgG responses peaked on
study day 42, leveled off by study day 70, and remained constant
through the remaining 6-month test period (Fig. 4C). In contrast,
IgG titers only slightly increased in mice immunized with Pfs25-
CP VLPs without adjuvant and never reached the 10,000 mark
(data not shown).
The SMFA analysis of sera collected after a single dose of Pfs25-
CP VLPs showed 100% TB activity on study day 70 in mice that
received $5.0 mg of the Pfs25 equivalent in the VLPs, whereas
doses of 1.0 and 0.2 mg of the Pfs25 equivalent elicited .99.5%
and 98.8% reduction, respectively (Table 3). All doses tested
showed a marked reduction in prevalence. The low dose (0.2 mg)
of Pfs25-CP VLPs showed a reduction in prevalence to 20% (4 of
20), while the 1.0 mg dose group reduced this even further to 10%.
In the control group of mice that received 25 mg of CP with
AlhydrogelH the intensity was 20.5 oocysts with high prevalence of
infection (19 of 20 mosquitos). At 6 months post vaccination,
.94% of TB activity was maintained at doses of $1.0 mg.
Furthermore, all serum samples in these groups showed a median
oocyst per mosquito count of 0 (Table 3). This reduction in
transmission was also observed on pooled sera collected at 168
days post-immunization. The highest Pfs25 dose group (25 mg)
reached complete TB at 6 months after a single vaccination. The
lowest dose group (0.2 mg) showed a reduction in prevalence to
35% and a 90.4% reduction in oocysts after 6 months. The 1.0
and 5.0 mg doses showed prevalence reduction to 25% and 5%
with 95.6% and 99.1% reduction in oocysts, respectively. While
the infection intensities are lower at the 6-month time point, the
overall trends of transmission reduction and TB are clear,
indicating that Pfs25-CP VLP is a potent TBV candidate.
Discussion
We have developed a plant-produced recombinant Pfs25-CP
VLP malaria vaccine candidate that elicits potent TB activity in
mice after immunization with low doses in combination with alum
Figure 2. Pfs25-CP VLP purity and identity. (A) Deduced amino acid sequence of Pfs25-CP with Pfs25 sequence underlined. Amino acids boxed
in the sequence were identified by N-terminal sequencing of the SDS-PAGE bands indicated. A Coomassie stain of an SDS-PAGE gel highlights the
Pfs25-CP fusion polypeptide (arrowhead ‘a’) and CP monomer polypeptides (arrowheads ‘b’ & ‘c’). N-terminal sequencing of ‘a’ identified the first 5
amino acids of Pfs25, while sequencing of ‘b & c’ identified residue 26 of AlMV CP. (B) Western blot analysis of Pfs25-CP VLPs with an anti-Pfs25 mAb
(left panel) and an anti-AlMV CP polyclonal serum (right panel).
doi:10.1371/journal.pone.0079538.g002
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adjuvant. We show for the first time complete TB after a single
dose of Pfs25-CP VLP that lasts at least 6 months.
Pfs25 protein expressed on the surface of the sexual stages of
Plasmodium [9] is a promising target for TBV development. Despite
challenges in expression of a correctly folded Pfs25 protein,
recombinant Pfs25 has been produced in a yeast eukaryotic
system. A truncated version of Pfs25 (ScPfs25H), with knocked out
N-linked glycosylation sites and a hexa-histidine tag to facilitate
purification, was successfully expressed in Saccharomyces cerevisiae
(ScPfs25H) [14]. Although ScPfs25H was not recognized by mAbs
specific to Pfs25, it elicited a strong antibody response with TB
activity in mice and non-human primates when adjuvanted with
Freund’s or MF59 [15]. The TB activity of ScPfs25H has been
shown to depend on correctly folded conformer A, the proportion
of which in total purified protein increased when Pfs25 was
expressed in P. pastoris (PpPfs25H-A) [16]. This conformer A-
enriched Pfs25 protein induced strong anti-Pfs25 and TB antibody
responses in mice [16] and humans when adjuvanted with
Montanide ISA 51 [17]. However, the Phase 1 clinical trial,
including a Pvs25 arm, was terminated prematurely due to the
appearance of systemic adverse reactions in some subjects,
contributed by the specific Pvs25 antigen/adjuvant combination
and not the Pvs25 antigen alone [17]. In both pre-clinical and
clinical studies, a consistent correlation was observed between the
titer of anti-Pfs25 antibodies and TB activity determined using the
membrane feeding assay [18]. Furthermore, chemical conjugation
of PpPfs25H-A to either EPA of P. aeruginosa or an outer
membrane protein complex of Neisseria meningitides was shown to
have a dramatically enhancing effect on both anti-Pfs25 and TB
antibody responses [19,20,21,22]. The PpPfs25-EPA conjugate
was recently shown to have nanoparticle characteristics with a size
distribution determined by light scattering to be from 5–25 nm
radius [48]. Formulations of this conjugate with AlhydrogelH may
further increase the apparent size due to the particulate nature of
the adjuvant. This finding relates the observations that the
PpPfs25-EPA conjugate enhances the immunogenicity of Pfs25
Figure 3. Pfs25-CP VLP particle analysis. (A) Negative stain transmission electron micrograph of Pfs25-CP VLPs shows highly uniform particles of
19.362.4 nm in diameter. (B) Transmission electron micrograph of Pfs25-CP VLPs labeled with anti-Pfs25 and gold-labeled anti-mouse antibodies
confirms the presence of Pfs25 on the particles. (C) DLS histogram showing a narrow size distribution for Pfs25-CP VLPs. The average hydrodynamic
radius is ,14 nm with a polydispersity of ,15%. (D) Analytical SEC showing a single, major eluting species confirmed by Western blot analysis (not
shown) to be Pfs25-CP VLP. The void volume of the SRT 1000 column (range 7.5 MDa –50 kDa) is indicated by (a) molecular weight standards
indicated by (b) for thyroglobulin, (c) for BSA and (d) for uracil.
doi:10.1371/journal.pone.0079538.g003
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with the general observation that particle-like structures have also
been shown to improve the immunogenicity of recombinant
subunit immunogens [49], including malaria antigens [50]. A
Phase 1 clinical trial of the Pfs25-EPA vaccine candidate
adjuvanted with AlhydrogelH began in the latter part of 2011
(http://www.clinicaltrials.gov/ct2/show/NCT01434381).
Plants represent an alternative system for expression of complex
eukaryotic proteins, including Pfs25. We have previously reported
on the production of soluble, full-length (lacking the glycosylpho-
Figure 4. Anti-Pfs25 IgG responses in mice determined by ELISA. (A) Average anti-Pfs25 IgG titers from mice immunized with two doses of
either 1.0 mg (circles) or 0.1 mg (squares) of Pfs25-CP VLPs, each with (open symbols) or without (filled symbols) AlhydrogelH, or 5.0 mg of CP only
(black line). (B) Average anti-Pfs25 IgG titers from mice immunized with two doses of either 1.0 mg (circles), 0.1 mg (squares) or 0.01 mg (diamonds) of
Pfs25-CP VLPs with AlhydrogelH. (C) Average anti-Pfs25 IgG titers elicited by a single administration of Pfs25-CP VLPs with AlhydrogelH at antigen
doses ranging from 0.2–25 mg. Data are represented as average values per group of mice 6 standard error of the mean.
doi:10.1371/journal.pone.0079538.g004
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sphatidyl-inositol anchor) Pfs25 variants in N. benthamiana plants.
Four variants of Pfs25 were engineered, Pfs25 with and without N-
linked glycosylation as well as fusions of these to a carrier molecule
lichenase (LicKM) [26], and shown to be monomeric in solution
[33]. Of these four previously reported Pfs25 variants, a stand-
alone non-glycosylated Pfs25 as well as both glycosylated and non-
glycosylated fusions of Pfs25 induced high titers of anti-Pfs25
antibodies with TB activity between 99–100% when administered
to mice intramuscularly with AlhydrogelH adjuvant [33]. These
results further indicated the potential of Pfs25 as a TBV against
malaria and highlighted the importance for a carrier molecule to
enhance immunogenicity and TB activity of Pfs25.
Here, we utilized a VLP as a vaccine strategy to enhance the
immunogenicity of our monomeric Pfs25MF1E vaccine candidate
[33] by displaying it on an AlMV CP VLP. Pfs25-CP VLPs were
transiently expressed in and purified from N. benthamiana plants
infiltrated with Agrobacteria carrying the plant virus-based ‘launch’
vector. VLPs possess the strongest protective immunogenicity
among subunit vaccines [34] and have been used as a highly
efficient platform for the development of human and veterinary
vaccine candidates [35]. While AlMV CP has been used
previously as a carrier for antigenic epitopes, this is the first
report of expression and decoration of the AlMV CP VLP with an
entire antigenic structure. Unlike our previously reported mono-
meric Pfs25 TBV candidates [33], Pfs25-CP VLP is a self-
assembling non-enveloped VLP. Purified Pfs25-CP VLPs were
shown to be highly consistent in size with an estimated 20–30%
incorporation of Pfs25 onto the VLP surface. Cleavage between
Pfs25 and CP is believed to be necessary for the formation of the
T = 1 icosahedral particles observed with Pfs25-CP VLPs, as well
as by the demonstrated lack of assembled VLPs in the absence of
cleavage [51,52] (FhCMB, unpublished observations).
Plant-produced Pfs25-CP VLPs were immunogenic and in-
duced TB activity in mice in the presence of the adjuvant
AlhydrogelH. In a two-dose vaccination regimen, doses of the
Pfs25 antigen ranging from 1.0 to 0.1 mg yielded sustained TB
activity with no detectable oocysts from day 42–168. As a
comparison, our monomeric Pfs25MF1E has been previously
shown to induce strong TB activity (99%) in mice at a 5 mg dose 3
weeks after a booster dose of vaccine [33]. The Pfs25-CP VLP
candidate showed comparable TB responses at a 50-fold lower
dose, indicating that the VLP structure may contribute to a more
potent vaccine.
The overall lower median oocyst numbers and prevalence in the
control and non-adjuvanted dose groups at 6 months compared
with day 70 may more closely reflect field-level infections. An
additional dose reduction experiment using the two-dose immu-
nization schedule reproduced the strong transmission reduction
trends. Overall, while some variation was observed in the TB data
following two-dose vaccination, SMFA data showed.98% TB for
Table 1. Evaluation of TB activity in immunized mouse sera by SMFA: two vaccine doses.
70 days 168 days
Pfs25 Adjuvant Prevalencea Intensityb % reductionc p-value Prevalencea Intensityb % reductionc p-value
1 mg None 90 9 (0–34) 0 .0.05 75 2 (0–8) 4.4 ns*
1 mg Alhydrogel 0 0 (0–0) 100 ,0.001 0 0 (0–0) 100 ,0.01
0.1 mg None 95 12 (0–34) 0 .0.05 95 3 (0–12) 0 ns*
0.1 mg Alhydrogel 0 0 (0–0) 100 ,0.001 0 0 (0–0) 100 ,0.01
0 mg (5 mg
CP**)d
Alhydrogel 91 13 (0–33) – – 65 1 (0–9) – –
aThe proportion (percentage) of mosquitoes infected.
bMedian number of oocysts per mosquito (range).
c% reduction = (mean control oocyst – mean test oocyst) 4 mean control oocyst)*100.
dControl.
*ns – not significant.
**CP – coat protein.
doi:10.1371/journal.pone.0079538.t001
Table 2. Evaluation of TB activity in immunized mouse sera by SMFA: dose reduction study.
42 days 140 days
Pfs25 Adjuvant Prevalencea Intensityb % reductionc p-value Prevalencea Intensityb % reductionc p-value
1 mg Alhydrogel 0 0 (0–0) 100 ,0.001 10 0 (0–2) 98 ,0.001
0.1 mg Alhydrogel 0 0 (0–0) 100 ,0.001 10 0 (0–1) 99 ,0.001
0.01 mg Alhydrogel 94 10.5 (0–39) 11 .0.05 90 4 (0–15) 51 .0.05
0 mg
(PBS*)d
Alhydrogel 100 14 (1–41) – – 90 9 (1–24) – –
aThe proportion (percentage) of mosquitoes infected.
bMedian number of oocysts (range).
c% reduction = (mean control oocyst – mean test oocyst) 4 mean control oocyst)*100.
dControl.
*PBS – phosphate buffered saline.
doi:10.1371/journal.pone.0079538.t002
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the two dose groups with AlhydrogelH. In addition to high TB
activity in the two-dose vaccination regimen, a single dose of
Pfs25-CP VLPs plus AlhydrogelH, in the range from 0.2 mg to
25 mg of Pfs25, also elicited serum antibodies that completely
blocked transmission in SMFA, and TB activity lasted up to 6
months post vaccination, further supporting the potential of Pfs25-
CP VLPs as a TBV candidate.
Taken together, our results demonstrate that immunization of
mice with Pfs25-CP VLPs using either a two-dose or a single-dose
vaccination regimen induced functional immune responses that
exhibited complete TB activity in SMFA. In both regimens, the
adjuvant AlhydrogelH was necessary to achieve and maintain the
functional antibody responses through the 6 months of the study.
Further studies on the Pfs25-CP VLP vaccine are planned to
include monitoring of the TB responses beyond 6 months, as well
as evaluation of the target in different animals species such as
rabbits and non-human primates. In addition, increasing target
representation on the VLP, further characterization of possible
host cell-derived contaminants, including endotoxin, and their
potential impact on the vaccine immunogenicity, as well as
enhanced formulation development will be undertaken to further
increase vaccine efficacy and stability. Indeed, preliminary pilot
scale Good Manufacturing Practice regulated production runs had
endotoxin levels of 181 EU/mg of product as assessed by
EndosafeH-MCSTM system (Charles River Laboratories), well
with acceptable levels for parenteral administration.
Efforts are now focused on the clinical development of the
Pfs25-CP VLP TBV candidate produced in plants using the
‘launch’ vector-based technology. This plant production system
has been extensively reviewed elsewhere [53,54,55] to include
comparisons with other traditional production platforms. In
addition, our system has proven to be scalable and suitable for
production of clinical grade material to support Phase 1 clinical
trials [56] (Cummings et al., manuscript submitted to Vaccine).
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